{
    "PMC5564609_3": [
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "P": "0.02",
                "Delayed gastric emptying": "32"
            },
            "measures": "[P, 0.02]",
            "outcomes": "[Delayed gastric emptying, 15 vs 32]"
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "P": "0.5",
                "Bleeding": "4"
            },
            "measures": "[P, 0.5]",
            "outcomes": "[Bleeding, 6 vs 4]"
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "P": "0.52",
                "Pancreatic fistula": "36"
            },
            "measures": "[P, 0.52]",
            "outcomes": "[Pancreatic fistula, 39 vs 36]"
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Grade A": "6"
            },
            "measures": "[Grade A, 8 vs 6]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Grade B": "6"
            },
            "measures": "[Grade B, 10 vs 6]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Grade C": "24"
            },
            "measures": "[Grade C, 21 vs 24]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Biliary fistula": "0"
            },
            "measures": "[Biliary fistula, 2 vs 0]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Wound infection": "3"
            },
            "measures": "[Wound infection, 5 vs 3]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Pulmonary complication": "4"
            },
            "measures": "[Pulmonary complication, 2 vs 4]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Skin orifice infection": "6"
            },
            "measures": "[Skin orifice infection, 1 vs 6]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Abdominal abscess": "0"
            },
            "measures": "[Abdominal abscess, 0]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Pancreatitis": "1"
            },
            "measures": "[Pancreatitis, 2 vs 1]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Sepsis": "0"
            },
            "measures": "[Sepsis, 1 vs 0]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Re-laparotomy": "1"
            },
            "measures": "[Re-laparotomy, 3 vs 1]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Mortality": "0"
            },
            "measures": "[Mortality, 0]",
            "outcomes": ""
        },
        {
            "subject": {
                "Parameters": "Conventional (n=83)",
                "Readmission (in 30 days)": "1"
            },
            "measures": "[Readmission (in 30 days), 1]",
            "outcomes": ""
        }
    ],
    "PMC3798558_1": [
        {
            "subject": {
                "study": "pancreatic cancer",
                "population": "case controls",
                "n_cases": "185",
                "n_controls": "1465"
            },
            "measures": "[age, sex, current BMI, BMI at age 20, cigarette pack-years, drinking, history of diabetes mellitus, family history of PC]",
            "outcomes": ""
        }
    ],
    "PMC5762325_3": [
        {
            "subject": {
                "Tumor tissue sample": "E-cadherin Low",
                "STYK1": "9",
                "Correlation coefficient": "-0.420",
                "P-value": "<0.001"
            },
            "measures": "[Tumor tissue sample, E-cadherin Low, STYK1, Correlation coefficient, P-value]",
            "outcomes": ""
        },
        {
            "subject": {
                "Tumor tissue sample": "E-cadherin High",
                "STYK1": "14"
            },
            "measures": "[Tumor tissue sample, E-cadherin High, STYK1]",
            "outcomes": ""
        },
        {
            "subject": {
                "Pancreatic cancer": "Correlation analysis"
            },
            "measures": "[Pancreatic cancer, Correlation analysis]",
            "outcomes": ""
        },
        {
            "subject": {
                "E-cadherin": "Low",
                "STYK1": "Low"
            },
            "measures": "[E-cadherin, STYK1]",
            "outcomes": ""
        },
        {
            "subject": {
                "E-cadherin": "High",
                "STYK1": "High"
            },
            "measures": "[E-cadherin, STYK1]",
            "outcomes": ""
        },
        {
            "subject": {
                "Correlation analysis": "between E-cadherin and STYK1 expression"
            },
            "measures": "[Correlation analysis, E-cadherin, STYK1]",
            "outcomes": ""
        },
        {
            "subject": {
                "expression": "in pancreatic cancer"
            },
            "measures": "[expression, pancreatic cancer]",
            "outcomes": ""
        },
        {
            "subject": {
                "Citations": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer"
            },
            "measures": "[Citations, Correlation analysis, E-cadherin, STYK1, pancreatic cancer]",
            "outcomes": ""
        }
    ],
    "PMC3798558_3": [
        {
            "subject": {
                "Haplotype": "1",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "R-squared": "0.15"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": [
                "[OR, 1.32]",
                "[CI, 1.01-1.71]",
                "[P-value, 0.042]"
            ]
        },
        {
            "subject": {
                "Haplotype": "2",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "Haplotype frequency": "0.240"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": [
                "[OR, 1.32]",
                "[CI, 1.01-1.71]",
                "[P-value, 0.042]"
            ]
        },
        {
            "subject": {
                "Haplotype": "3",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "Haplotype frequency": "0.319"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": [
                "[OR, 1.00]",
                "[CI, ref.]",
                "[P-value, ]"
            ]
        },
        {
            "subject": {
                "Haplotype": "4",
                "SNP 1": "rs1799782",
                "SNP 2": "rs25487",
                "Haplotype frequency": "0.002"
            },
            "measures": "[Haplotype, haplotype TA]",
            "outcomes": [
                "[OR, N.E.]",
                "[CI, N.E.]",
                "[P-value, N.E.]"
            ]
        },
        {
            "subject": {
                "Caption": "Haplotype frequencies of XRCC1, and odds ratios for pancreatic cancer associated with XRCC1 haplotype"
            },
            "measures": "[Table, Table 3]",
            "outcomes": ""
        },
        {
            "subject": {
                "Multivariable adjustment": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC"
            },
            "measures": "[Method, Haplotype-effects logistic regression for case-control data]",
            "outcomes": ""
        },
        {
            "subject": {
                "Abbreviation": "OR, odds ratio"
            },
            "measures": "[Footnote, a]",
            "outcomes": ""
        },
        {
            "subject": {
                "SNP 1": "rs1799782"
            },
            "measures": "[Footnote, a]",
            "outcomes": ""
        },
        {
            "subject": {
                "SNP 2": "rs25487"
            },
            "measures": "[Footnote, a]",
            "outcomes": ""
        },
        {
            "subject": {
                "Multivariable adjustment by age": "sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC"
            },
            "measures": "[Footnote, b]",
            "outcomes": ""
        },
        {
            "subject": {
                "N.E.": "not estimated"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "ref.": "reference"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "PC": "pancreatic cancer"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "XRCC1": "X-ray cross-complementing group 1"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "CI": "confidence interval"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "P-value": "statistical significance"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "OR": "odds ratio"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype": "haplotype CA"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype": "haplotype CG"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype": "haplotype TA"
            },
            "measures": "[Footnote, ]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.439"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.433"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.442"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.240"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.274"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.239"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.319"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.292"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.318"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.002"
            },
            "measures": "[Haplotype, haplotype TA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "<0.001"
            },
            "measures": "[Haplotype, haplotype TA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Haplotype frequency": "0.002"
            },
            "measures": "[Haplotype, haplotype TA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Adjusted OR": "1.00"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Adjusted OR": "1.32"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": ""
        },
        {
            "subject": {
                "Adjusted OR": "1.05"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "Adjusted OR": "N.E."
            },
            "measures": "[Haplotype, haplotype TA]",
            "outcomes": ""
        },
        {
            "subject": {
                "P-value": "0.042"
            },
            "measures": "[Haplotype, haplotype CA]",
            "outcomes": ""
        },
        {
            "subject": {
                "P-value": ""
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "P-value": "0.691"
            },
            "measures": "[Haplotype, haplotype CG]",
            "outcomes": ""
        },
        {
            "subject": {
                "P-value": "N.E."
            },
            "measures": "[Haplotype, haplotype TA]",
            "outcomes": ""
        }
    ],
    "PMC4423458_3": [
        {
            "subject": {
                "Protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                "Accession": "70906435",
                "MW": "56",
                "Average SC": "138.8",
                "NSAF ratio": "2.2",
                "P-value": "0.01481"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "C4b-binding protein alpha chain precursor",
                "Accession": "4502503",
                "MW": "67",
                "Average SC": "37.3",
                "NSAF ratio": "2.3",
                "P-value": "0.04311"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Serum albumin pre-pro-protein",
                "Accession": "4502027",
                "MW": "69",
                "Average SC": "986.0",
                "NSAF ratio": "2.4",
                "P-value": "0.00006"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Vitamin D-binding protein isoform 1 precursor",
                "Accession": "32483410",
                "MW": "53",
                "Average SC": "51.9",
                "NSAF ratio": "2.4",
                "P-value": "0.03919"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Kininogen-1 isoform 2 precursor",
                "Accession": "4504893",
                "MW": "48",
                "Average SC": "21.3",
                "NSAF ratio": "3.8",
                "P-value": "0.01109"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Alpha-2-macroglobulin precursor",
                "Accession": "66932947",
                "MW": "163",
                "Average SC": "127.9",
                "NSAF ratio": "3.9",
                "P-value": "0.00618"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Haptoglobin isoform 1 pre-pro-protein",
                "Accession": "4826762",
                "MW": "45",
                "Average SC": "83.8",
                "NSAF ratio": "4.2",
                "P-value": "0.00024"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                "Accession": "70906439",
                "MW": "52",
                "Average SC": "89.3",
                "NSAF ratio": "4.3",
                "P-value": "0.00133"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Complement C3 precursor",
                "Accession": "115298678",
                "MW": "187",
                "Average SC": "174.7",
                "NSAF ratio": "4.3",
                "P-value": "0.00612"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Myeloperoxidase precursor",
                "Accession": "4557759",
                "MW": "84",
                "Average SC": "70.2",
                "NSAF ratio": "5.3",
                "P-value": "0.02501"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Apolipoprotein A-I pre-pro-protein",
                "Accession": "4557321",
                "MW": "31",
                "Average SC": "29.8",
                "NSAF ratio": "5.7",
                "P-value": "0.02170"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Fibrinogen alpha chain isoform alpha-E pre-pro-protein",
                "Accession": "4503689",
                "MW": "95",
                "Average SC": "63.3",
                "NSAF ratio": "6.4",
                "P-value": "0.00031"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Alpha-2-HS-glycoprotein pre-pro-protein",
                "Accession": "156523970",
                "MW": "39",
                "Average SC": "7.3",
                "NSAF ratio": "6.5",
                "P-value": "0.00173"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Ceruloplasmin precursor",
                "Accession": "4557485",
                "MW": "122",
                "Average SC": "47.3",
                "NSAF ratio": "7.5",
                "P-value": "0.00114"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "PREDICTED: complement C4-A isoform 1",
                "Accession": "341916194",
                "MW": "193",
                "Average SC": "32.1",
                "NSAF ratio": "7.7",
                "P-value": "0.01791"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Alpha-1B-glycoprotein precursor",
                "Accession": "21071030",
                "MW": "54",
                "Average SC": "10.9",
                "NSAF ratio": "8.3",
                "P-value": "0.00468"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor",
                "Accession": "31542984",
                "MW": "103",
                "Average SC": "5.5",
                "NSAF ratio": "35.4",
                "P-value": "0.00484"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        },
        {
            "subject": {
                "Protein": "Apolipoprotein B-100 precursor",
                "Accession": "105990532",
                "MW": "516",
                "Average SC": "49.3",
                "NSAF ratio": "55.7",
                "P-value": "0.02595"
            },
            "measures": "[MW, SC, NSAF ratio, P-value]",
            "outcomes": "[cancer, control]"
        }
    ],
    "PMC4190529_6": [
        {
            "subject": {
                "Treatment": "gemcitabine",
                "Control": "5-fluorouracil",
                "Phase": "3",
                "Median Survival": "5.7",
                "One-Year Survival": "4.2",
                "Side Effects": "18%",
                "FDA Approval": "1996"
            },
            "measures": "[Treatment, FDA Approved]",
            "outcomes": [
                "[Median Survival, 5.7]",
                "[One-Year Survival, 4.2]"
            ]
        },
        {
            "subject": {
                "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                "Control": "gemcitabine",
                "Phase": "3",
                "Median Survival": "6.4",
                "One-Year Survival": "6",
                "Side Effects": "24%",
                "FDA Approval": "2005"
            },
            "measures": "[Treatment, FDA Approved]",
            "outcomes": [
                "[Median Survival, 6.4]",
                "[One-Year Survival, 6]"
            ]
        },
        {
            "subject": {
                "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                "Control": "gemcitabine",
                "Phase": "3",
                "Median Survival": "8.5",
                "One-Year Survival": "6.7",
                "Side Effects": "35%",
                "FDA Approval": "2013"
            },
            "measures": "[Treatment, FDA Approved]",
            "outcomes": [
                "[Median Survival, 8.5]",
                "[One-Year Survival, 6.7]"
            ]
        },
        {
            "subject": {
                "Treatment": "FOLFIRINOX *",
                "Control": "gemcitabine",
                "Phase": "2/3",
                "Median Survival": "11.1",
                "One-Year Survival": "6.8",
                "Side Effects": "48.4%",
                "FDA Approval": "n/a"
            },
            "measures": "[Treatment, FDA Approved]",
            "outcomes": [
                "[Median Survival, 11.1]",
                "[One-Year Survival, 6.8]"
            ]
        },
        {
            "subject": {
                "Treatment": "cell encapsulation + ifosfamide",
                "Control": "5-fluorouracil",
                "Phase": "2",
                "Median Survival": "10",
                "One-Year Survival": "5",
                "Side Effects": "36%",
                "FDA Approval": "n/a"
            },
            "measures": "[Treatment, FDA Approved]",
            "outcomes": [
                "[Median Survival, 10]",
                "[One-Year Survival, 5]"
            ]
        },
        {
            "subject": {
                "Citation": "Oxaliplatin, irinotecan, fluorouracil and leucovorin",
                "Toxicity": "Grade 3 or Grade 4 NCI",
                "Survival": "9.5 months"
            },
            "measures": "[Citation, NCI Toxicity]",
            "outcomes": "[Survival, 9.5 months]"
        },
        {
            "subject": {
                "Caption": "Summary of recent trial data for pancreatic cancer treatments"
            },
            "measures": "[Caption, Pancreatic Cancer Treatments]",
            "outcomes": ""
        }
    ],
    "PMC5675623_3": [
        {
            "subject": {
                "Variable": "ECOG performance status",
                "Contrast": "> 0 vs. 0",
                "Hazard ratio (95% CI)": "1.47 (0.90, 2.41)",
                "P value": "0.12"
            },
            "measures": "[Variable, Hazard ratio (95% CI)]",
            "outcomes": "[ECOG performance status, 0.12]"
        },
        {
            "subject": {
                "Variable": "Liver metastases",
                "Contrast": "Yes vs. No",
                "Hazard ratio (95% CI)": "1.72 (1.01, 2.91)",
                "P value": "0.045"
            },
            "measures": "[Variable, Hazard ratio (95% CI)]",
            "outcomes": "[Liver metastases, 0.045]"
        },
        {
            "subject": {
                "Variable": "No. of metastatic sites",
                "Contrast": ">2 vs. <= 2",
                "Hazard ratio (95% CI)": "1.33 (0.9, 2.25)",
                "P value": "0.28"
            },
            "measures": "[Variable, Hazard ratio (95% CI)]",
            "outcomes": "[No. of metastatic sites, 0.28]"
        },
        {
            "subject": {
                "Variable": "Prior radiation therapy",
                "Contrast": "Yes vs. No",
                "Hazard ratio (95% CI)": "1.58 (0.95, 2.61)",
                "P value": "0.077"
            },
            "measures": "[Variable, Hazard ratio (95% CI)]",
            "outcomes": "[Prior radiation therapy, 0.077]"
        },
        {
            "subject": {
                "Variable": "Prior FOLFIRINOX",
                "Contrast": "Yes vs. No",
                "Hazard ratio (95% CI)": "1.73 (1.01, 2.98)",
                "P value": "0.046"
            },
            "measures": "[Variable, Hazard ratio (95% CI)]",
            "outcomes": "[Prior FOLFIRINOX, 0.046]"
        },
        {
            "subject": {
                "Variable": "Prior gemcitabine plus nab-paclitaxel treatment",
                "Contrast": "Yes vs. No",
                "Hazard ratio (95% CI)": "1.08 (0.58, 2.01)",
                "P value": "0.80"
            },
            "measures": "[Variable, Hazard ratio (95% CI)]",
            "outcomes": "[Prior gemcitabine plus nab-paclitaxel treatment, 0.80]"
        },
        {
            "subject": {
                "Caption": "Results of multivariate Cox proportional hazards regression analysis performed to assess the impact of multiple factors on overall survival (OS) from first phase I treatment"
            },
            "measures": "[Citation, FOLFIRINOX, 5-fluorouracil, oxaliplatin, and irinotecan]",
            "outcomes": ""
        },
        {
            "subject": {
                "Variable": "ECOG performance status",
                "Variable type": "Continuous"
            },
            "measures": "[Variable, ECOG performance status]",
            "outcomes": ""
        },
        {
            "subject": {
                "Variable": "Liver metastases",
                "Variable type": "Binary"
            },
            "measures": "[Variable, Liver metastases]",
            "outcomes": ""
        },
        {
            "subject": {
                "Variable": "No. of metastatic sites",
                "Variable type": "Continuous"
            },
            "measures": "[Variable, No. of metastatic sites]",
            "outcomes": ""
        },
        {
            "subject": {
                "Variable": "Prior radiation therapy",
                "Variable type": "Binary"
            },
            "measures": "[Variable, Prior radiation therapy]",
            "outcomes": ""
        },
        {
            "subject": {
                "Variable": "Prior FOLFIRINOX",
                "Variable type": "Binary"
            },
            "measures": "[Variable, Prior FOLFIRINOX]",
            "outcomes": ""
        },
        {
            "subject": {
                "Variable": "Prior gemcitabine plus nab-paclitaxel treatment",
                "Variable type": "Binary"
            },
            "measures": "[Variable, Prior gemcitabine plus nab-paclitaxel treatment]",
            "outcomes": ""
        },
        {
            "subject": {
                "Metric": "Hazard ratio (95% CI)"
            },
            "measures": "[Outcome, 0.12]",
            "outcomes": ""
        },
        {
            "subject": {
                "Metric": "Hazard ratio (95% CI)"
            },
            "measures": "[Outcome, 0.045]",
            "outcomes": ""
        },
        {
            "subject": {
                "Metric": "Hazard ratio (95% CI)"
            },
            "measures": "[Outcome, 0.28]",
            "outcomes": ""
        },
        {
            "subject": {
                "Metric": "Hazard ratio (95% CI)"
            },
            "measures": "[Outcome, 0.077]",
            "outcomes": ""
        },
        {
            "subject": {
                "Metric": "Hazard ratio (95% CI)"
            },
            "measures": "[Outcome, 0.046]",
            "outcomes": ""
        },
        {
            "subject": {
                "Metric": "Hazard ratio (95% CI)"
            },
            "measures": "[Outcome, 0.80]",
            "outcomes": ""
        }
    ],
    "PMC4742219_3": [
        {
            "subject": {
                "Variable": "Age",
                "HR": "1.00 (0.98, 1.02)",
                "P value": "0.874"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[1.00 (0.98, 1.02), 0.874]"
        },
        {
            "subject": {
                "Variable": "Gender (female vs. male)",
                "HR": "0.89 (0.60, 1.31)",
                "P value": "0.544"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[0.89 (0.60, 1.31), 0.544]"
        },
        {
            "subject": {
                "Variable": "Tumor size",
                "HR": "1.13 (0.97, 1.33)",
                "P value": "0.127"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[1.13 (0.97, 1.33), 0.127]"
        },
        {
            "subject": {
                "Variable": "Tumor grade",
                "Grade II vs. I": "1.00 (0.69, 1.45)",
                "P value": "0.991"
            },
            "measures": "[Variable, Grade II vs. I, P value]",
            "outcomes": "[1.00 (0.69, 1.45), 0.991]"
        },
        {
            "subject": {
                "Variable": "Tumor grade",
                "Grade III vs. I": "0.93 (0.27, 3.17)",
                "P value": "0.906"
            },
            "measures": "[Variable, Grade III vs. I, P value]",
            "outcomes": "[0.93 (0.27, 3.17), 0.906]"
        },
        {
            "subject": {
                "Variable": "Lymph Nodes (yes vs. no)",
                "HR": "1.39 (0.81, 2.38)",
                "P value": "0.229"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[1.39 (0.81, 2.38), 0.229]"
        },
        {
            "subject": {
                "Variable": "Margin (positive vs. negative)",
                "HR": "1.54 (1.06, 2.25)",
                "P value": "0.025"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[1.54 (1.06, 2.25), 0.025]"
        },
        {
            "subject": {
                "Variable": "Vascular invasion (yes vs. no)",
                "HR": "0.99 (0.69, 1.42)",
                "P value": "0.967"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[0.99 (0.69, 1.42), 0.967]"
        },
        {
            "subject": {
                "Variable": "Perineural invasion (yes vs. no)",
                "HR": "2.19 (0.87, 5.49)",
                "P value": "0.097"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[2.19 (0.87, 5.49), 0.097]"
        },
        {
            "subject": {
                "Variable": "Time from surgery to first recurrence",
                "HR": "1.00 (0.98, 1.02)",
                "P value": "0.883"
            },
            "measures": "[Variable, Hazard Ratio, P value]",
            "outcomes": "[1.00 (0.98, 1.02), 0.883]"
        },
        {
            "subject": {
                "Variable": "Recurrence pattern",
                "Lung + Other vs. Lung": "1.25 (0.63, 2.48)",
                "P value": "0.516"
            },
            "measures": "[Variable, Lung + Other vs. Lung, P value]",
            "outcomes": "[1.25 (0.63, 2.48), 0.516]"
        },
        {
            "subject": {
                "Variable": "Recurrence pattern",
                "Liver + Other vs. Lung": "1.91 (1.10, 3.31)",
                "P value": "0.022"
            },
            "measures": "[Variable, Liver + Other vs. Lung, P value]",
            "outcomes": "[1.91 (1.10, 3.31), 0.022]"
        },
        {
            "subject": {
                "Variable": "Recurrence pattern",
                "Peritoneal vs. Lung": "6.32 (3.12, 12.79)",
                "P value": "< 0.001"
            },
            "measures": "[Variable, Peritoneal vs. Lung, P value]",
            "outcomes": "[6.32 (3.12, 12.79), < 0.001]"
        },
        {
            "subject": {
                "Variable": "Recurrence pattern",
                "Local vs. Lung": "2.09 (1.10, 4.00)",
                "P value": "0.025"
            },
            "measures": "[Variable, Local vs. Lung, P value]",
            "outcomes": "[2.09 (1.10, 4.00), 0.025]"
        }
    ],
    "PMC4941379_3": [
        {
            "subject": {
                "Chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "315",
                "Cases": "5",
                "Crude incidence rate": "151.20",
                "HR2": "12.51 (3.57-43.22)",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "315",
                "Cases": "5",
                "HR2": "12.51 (3.57-43.22)",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "315",
                "HR2": "12.51 (3.57-43.22)",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "315",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "Present",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "1,984",
                "Cases": "2",
                "Crude incidence rate": "9.54",
                "HR1": "0.79 (0.15-4.08)",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "1,984",
                "Cases": "2",
                "HR1": "0.79 (0.15-4.08)",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Sample": "1,984",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        },
        {
            "subject": {
                "Chronic atrophic gastritis": "None",
                "H. pylori infection": "IgG+/CagA+",
                "Citation": "Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence interval; H. pylori, Helicobacter pylori; HR, hazard ratio.\u2020Per 100,000 person-years.\u2021Adjusted for age, sex, education level, smoking status and alcohol consumption. HR1, comparing participants with and without chronic atrophic gastritis. HR2, comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection."
            }
        }
    ],
    "PMC3987090_5": [
        {
            "subject": {
                "Study": "An X et al",
                "Year": "2010",
                "n": "89",
                "Number of patients with NLR >5": "16 (17.9)",
                "Overall survival (NLR >5 vs. \u22645)": "2.4 versus 7.7",
                "Hazard ratio": "HR = 4.49, P = 0.013"
            },
            "measures": "[Study, Citation, Year, n, Number of patients with NLR >5, Overall survival (NLR >5 vs. \u22645), Hazard ratio]",
            "outcomes": "[Prognostic factor, Independent, OS, Palliative chemotherapy, APC patients]"
        },
        {
            "subject": {
                "Study": "Wang DS et al",
                "Year": "2012",
                "n": "86",
                "Number of patients with NLR >5": "12 (13.9)",
                "Overall survival (NLR >5 vs. \u22645)": "5.8 versus 10.2",
                "Hazard ratio": "NA"
            },
            "measures": "[Study, Citation, Year, n, Number of patients with NLR >5, Overall survival (NLR >5 vs. \u22645), Hazard ratio]",
            "outcomes": "[Prognostic factor, Independent, OS, Palliative chemotherapy, APC patients]"
        },
        {
            "subject": {
                "Study": "Stotz M et al",
                "Year": "2013",
                "n": "261",
                "Number of patients with NLR >5": "79 (30.3)",
                "Hazard ratio": "HR = 2.53, P < 0.01"
            },
            "measures": "[Study, Citation, Year, n, Number of patients with NLR >5, Hazard ratio]",
            "outcomes": "[Prognostic factor, Independent, OS, Palliative chemotherapy, APC patients]"
        },
        {
            "subject": {
                "Study": "Our study",
                "Year": "2013",
                "n": "253",
                "Number of patients with NLR >5": "40 (15.8)",
                "Overall survival (NLR >5 vs. \u22645)": "6.0 versus 12.8",
                "Hazard ratio": "HR = 1.95, P < 0.01"
            },
            "measures": "[Study, Citation, Year, n, Number of patients with NLR >5, Overall survival (NLR >5 vs. \u22645), Hazard ratio]",
            "outcomes": "[Prognostic factor, Independent, OS, Palliative chemotherapy, APC patients]"
        },
        {
            "subject": {
                "Caption": "Summary of published studies reporting the association between NLR and the prognosis of APC patients receiving chemotherapy"
            },
            "measures": "[Context, Published studies, APC patients, Palliative chemotherapy]",
            "outcomes": ""
        },
        {
            "subject": {
                "Citations": "The present results are in line with those of previous studies 16,17 reporting that elevated NLR was an independent prognostic factor for OS in APC patients receiving palliative chemotherapy"
            },
            "measures": "[Context, Previous studies, APC patients, Palliative chemotherapy]",
            "outcomes": ""
        },
        {
            "subject": {
                "Citations": "The proportion of patients with a pretreatment NLR of >5 in existing research are comparable across studies"
            },
            "measures": "[Context, Existing research, APC patients]",
            "outcomes": ""
        }
    ],
    "PMC3544459_4": [
        {
            "subject": {
                "Condition": "No",
                "Median survival time (months)": "33.2 \u00b1 1.8",
                "P value (log-rank)": "0.049",
                "HR (95% CI)": "1.0",
                "P": "0.036"
            },
            "measures": "[Condition, No]",
            "outcomes": "[Survival time, 33.2 \u00b1 1.8, P value, 0.049, HR, 1.0, P, 0.050, HR, 1.0, P, 0.036]"
        },
        {
            "subject": {
                "Condition": "Yes",
                "Median survival time (months)": "24.6 \u00b1 2.5",
                "HR (95% CI)": "1.29 (1.02\u20131.64)"
            },
            "measures": "[Condition, Yes]",
            "outcomes": "[Survival time, 24.6 \u00b1 2.5, HR, 1.27 (1.00\u20131.60), HR, 1.29 (1.02\u20131.64)]"
        },
        {
            "subject": {
                "Perineural invasion": "No",
                "Median survival time (months)": "51.7 \u00b1 31.1",
                "P value (log-rank)": "<0.001",
                "HR (95% CI)": "1.0",
                "P": "0.019"
            },
            "measures": "[Perineural invasion, No]",
            "outcomes": "[Survival time, 51.7 \u00b1 31.1, P value, <0.001, HR, 1.0, P, <0.001, HR, 1.0, P, 0.019]"
        },
        {
            "subject": {
                "Perineural invasion": "Yes",
                "Median survival time (months)": "29.4 \u00b1 1.64",
                "HR (95% CI)": "1.60 (1.08\u20132.36)"
            },
            "measures": "[Perineural invasion, Yes]",
            "outcomes": "[Survival time, 29.4 \u00b1 1.64, HR, 2.01 (1.38\u20132.93), HR, 1.60 (1.08\u20132.36)]"
        },
        {
            "subject": {
                "Margin status": "Negative",
                "Median survival time (months)": "33.6 \u00b1 1.7",
                "P value (log-rank)": "<0.001",
                "HR (95% CI)": "1.0",
                "P": "0.003"
            },
            "measures": "[Margin status, Negative]",
            "outcomes": "[Survival time, 33.6 \u00b1 1.7, P value, <0.001, HR, 1.0, P, <0.001, HR, 1.0, P, 0.003]"
        },
        {
            "subject": {
                "Margin status": "Positive",
                "Median survival time (months)": "24.8 \u00b1 2.6",
                "HR (95% CI)": "1.47 (1.14\u20131.90)"
            },
            "measures": "[Margin status, Positive]",
            "outcomes": "[Survival time, 24.8 \u00b1 2.6, HR, 1.62 (1.27\u20132.08), HR, 1.47 (1.14\u20131.90)]"
        },
        {
            "subject": {
                "Node status": "Negative",
                "Median survival time (months)": "38.6 \u00b1 5.3",
                "P value (log-rank)": "<0.001",
                "HR (95% CI)": "1.0",
                "P": "0.002"
            },
            "measures": "[Node status, Negative]",
            "outcomes": "[Survival time, 38.6 \u00b1 5.3, P value, <0.001, HR, 1.0, P, <0.001, HR, 1.0, P, 0.002]"
        },
        {
            "subject": {
                "Node status": "Positive",
                "Median survival time (months)": "27.5 \u00b1 1.3",
                "HR (95% CI)": "1.45 (1.14\u20131.83)"
            },
            "measures": "[Node status, Positive]",
            "outcomes": "[Survival time, 27.5 \u00b1 1.3, HR, 1.70 (1.35\u20132.15), HR, 1.45 (1.14\u20131.83)]"
        },
        {
            "subject": {
                "Differentiation": "Well\u2013moderate",
                "Median survival time (months)": "35.9 \u00b1 2.68",
                "P value (log-rank)": "<0.001",
                "HR (95% CI)": "1.0",
                "P": "<0.001"
            },
            "measures": "[Differentiation, Well\u2013moderate]",
            "outcomes": "[Survival time, 35.9 \u00b1 2.68, P value, <0.001, HR, 1.0, P, <0.001, HR, 1.0, P, <0.001]"
        },
        {
            "subject": {
                "Differentiation": "Poor",
                "Median survival time (months)": "26.0 \u00b1 1.77",
                "HR (95% CI)": "1.63 (1.32\u20132.02)"
            },
            "measures": "[Differentiation, Poor]",
            "outcomes": "[Survival time, 26.0 \u00b1 1.77, HR, 1.63 (1.32\u20132.02), HR, 1.63 (1.32\u20132.02)]"
        }
    ],
    "PMC3497287_3": [
        {
            "subject": {
                "Inherited Syndrome": "Lynch Syndrome",
                "Mutated Gene": "Mismatch Repair Genes (MMR): MLH1, MSH2, MSH6 and PMS2"
            },
            "measures": "[Inherited Syndrome, Mutated Gene]",
            "outcomes": "[Lynch Syndrome, Mismatch Repair Genes (MMR): MLH1, MSH2, MSH6 and PMS2]"
        },
        {
            "subject": {
                "Inherited Syndrome": "Peutz-Jeghers Syndrome",
                "Mutated Gene": "STK11/LKB1"
            },
            "measures": "[Inherited Syndrome, Mutated Gene]",
            "outcomes": "[Peutz-Jeghers Syndrome, STK11/LKB1]"
        },
        {
            "subject": {
                "Inherited Syndrome": "Hereditary Breast Cancer",
                "Mutated Gene": "BRCA1/BRCA2"
            },
            "measures": "[Inherited Syndrome, Mutated Gene]",
            "outcomes": "[Hereditary Breast Cancer, BRCA1/BRCA2]"
        },
        {
            "subject": {
                "Inherited Syndrome": "Familial Atypical Multiple Mole Melanoma",
                "Mutated Gene": "CDKN2A mutation"
            },
            "measures": "[Inherited Syndrome, Mutated Gene]",
            "outcomes": "[Familial Atypical Multiple Mole Melanoma, CDKN2A mutation]"
        }
    ],
    "PMC4741511_2": [
        {
            "subject": {
                "study_population": "MAPS phase II study population",
                "LDH_serum_levels": "stratified according to LDH serum levels",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "PFS": "7.6 months",
                "OS": "12.7 months",
                "p_value": "0.05"
            },
            "measures": "[study_population, LDH_serum_levels, treatment]",
            "outcomes": ""
        },
        {
            "subject": {
                "study_population": "MAPS phase II study population",
                "LDH_serum_levels": "stratified according to LDH serum levels",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "PFS": "2.8 months",
                "OS": "5.9 months",
                "p_value": "0.0012"
            },
            "measures": "[study_population, LDH_serum_levels, treatment]",
            "outcomes": ""
        },
        {
            "subject": {
                "study_population": "MAPS phase II study population",
                "LDH_serum_levels": "stratified according to LDH serum levels",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "PFS": "3.3 months",
                "OS": "8.6 months",
                "p_value": "0.05"
            },
            "measures": "[study_population, LDH_serum_levels, treatment]",
            "outcomes": ""
        },
        {
            "subject": {
                "study_population": "MAPS phase II study population",
                "LDH_serum_levels": "stratified according to LDH serum levels",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "PFS": "2.2 months",
                "OS": "5.2 months",
                "p_value": "0.05"
            },
            "measures": "[study_population, LDH_serum_levels, treatment]",
            "outcomes": ""
        }
    ],
    "PMC5522086_3": [
        {
            "subject": {
                "Upstream Regulator": "TP53",
                "Log Ratio": "-2.52",
                "Activation z-score": "-2.353",
                "P-value of overlap": "3.34\u00d710^-32"
            },
            "measures": "[Upstream Regulator, Inhibition]",
            "outcomes": [
                "[Log Ratio, -2.52]",
                "[Activation z-score, -3.977]",
                "[P-value of overlap, 4.62\u00d710^-13]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "NUPR1",
                "Log Ratio": "-2.52",
                "Activation z-score": "-3.977",
                "P-value of overlap": "4.62\u00d710^-13"
            },
            "measures": "[Upstream Regulator, NUPR1]",
            "outcomes": [
                "[Log Ratio, -2.52]",
                "[Activation z-score, -3.977]",
                "[P-value of overlap, 4.62\u00d710^-13]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "NKX2-3",
                "Activation z-score": "-3.455",
                "P-value of overlap": "5.88\u00d710^-12"
            },
            "measures": "[Upstream Regulator, NKX2-3]",
            "outcomes": [
                "[Activation z-score, -3.455]",
                "[P-value of overlap, 5.88\u00d710^-12]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "HNF1A",
                "Activation z-score": "-2.359",
                "P-value of overlap": "8.82\u00d710^-12"
            },
            "measures": "[Upstream Regulator, HNF1A]",
            "outcomes": [
                "[Activation z-score, -2.359]",
                "[P-value of overlap, 8.82\u00d710^-12]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "CDKN2A",
                "Log Ratio": "1.737",
                "Activation z-score": "-3.219",
                "P-value of overlap": "1.34\u00d710^-11"
            },
            "measures": "[Upstream Regulator, CDKN2A]",
            "outcomes": [
                "[Log Ratio, 1.737]",
                "[Activation z-score, -3.219]",
                "[P-value of overlap, 1.34\u00d710^-11]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "estrogen receptor",
                "Activation z-score": "-2.299",
                "P-value of overlap": "9.57\u00d710^-10"
            },
            "measures": "[Upstream Regulator, estrogen receptor]",
            "outcomes": [
                "[Activation z-score, -2.299]",
                "[P-value of overlap, 9.57\u00d710^-10]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "RB1",
                "Activation z-score": "-4.286",
                "P-value of overlap": "3.74\u00d710^-08"
            },
            "measures": "[Upstream Regulator, RB1]",
            "outcomes": [
                "[Activation z-score, -4.286]",
                "[P-value of overlap, 3.74\u00d710^-08]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "TCF3",
                "Activation z-score": "-3.116",
                "P-value of overlap": "4.32\u00d710^-08"
            },
            "measures": "[Upstream Regulator, TCF3]",
            "outcomes": [
                "[Activation z-score, -3.116]",
                "[P-value of overlap, 4.32\u00d710^-08]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "TRIM24",
                "Activation z-score": "-3.714",
                "P-value of overlap": "6.26\u00d710^-07"
            },
            "measures": "[Upstream Regulator, TRIM24]",
            "outcomes": [
                "[Activation z-score, -3.714]",
                "[P-value of overlap, 6.26\u00d710^-07]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "BCL6",
                "Activation z-score": "-2.313",
                "P-value of overlap": "1.60\u00d710^-06"
            },
            "measures": "[Upstream Regulator, BCL6]",
            "outcomes": [
                "[Activation z-score, -2.313]",
                "[P-value of overlap, 1.60\u00d710^-06]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "NR5A2",
                "Log Ratio": "-2.876",
                "Activation z-score": "-2.7",
                "P-value of overlap": "7.26\u00d710^-06"
            },
            "measures": "[Upstream Regulator, NR5A2]",
            "outcomes": [
                "[Log Ratio, -2.876]",
                "[Activation z-score, -2.7]",
                "[P-value of overlap, 7.26\u00d710^-06]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "SATB1",
                "Log Ratio": "-0.814",
                "Activation z-score": "-2.003",
                "P-value of overlap": "1.09\u00d710^-05"
            },
            "measures": "[Upstream Regulator, SATB1]",
            "outcomes": [
                "[Log Ratio, -0.814]",
                "[Activation z-score, -2.003]",
                "[P-value of overlap, 1.09\u00d710^-05]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "IRF4",
                "Log Ratio": "2.115",
                "Activation z-score": "-2.41",
                "P-value of overlap": "4.24\u00d710^-05"
            },
            "measures": "[Upstream Regulator, IRF4]",
            "outcomes": [
                "[Log Ratio, 2.115]",
                "[Activation z-score, -2.41]",
                "[P-value of overlap, 4.24\u00d710^-05]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "RBL1",
                "Activation z-score": "-3.124",
                "P-value of overlap": "1.72\u00d710^-04"
            },
            "measures": "[Upstream Regulator, RBL1]",
            "outcomes": [
                "[Activation z-score, -3.124]",
                "[P-value of overlap, 1.72\u00d710^-04]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "SPDEF",
                "Activation z-score": "-2.887",
                "P-value of overlap": "2.39\u00d710^-04"
            },
            "measures": "[Upstream Regulator, SPDEF]",
            "outcomes": [
                "[Activation z-score, -2.887]",
                "[P-value of overlap, 2.39\u00d710^-04]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "Activation",
                "Activation z-score": "2.924",
                "P-value of overlap": "5.78\u00d710^-19"
            },
            "measures": "[Upstream Regulator, Activation]",
            "outcomes": [
                "[Activation z-score, 2.924]",
                "[P-value of overlap, 5.78\u00d710^-19]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "STAT3",
                "Activation z-score": "2.924",
                "P-value of overlap": "5.78\u00d710^-19"
            },
            "measures": "[Upstream Regulator, STAT3]",
            "outcomes": [
                "[Activation z-score, 2.924]",
                "[P-value of overlap, 5.78\u00d710^-19]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "CTNNB1",
                "Activation z-score": "3.359",
                "P-value of overlap": "1.99\u00d710^-15"
            },
            "measures": "[Upstream Regulator, CTNNB1]",
            "outcomes": [
                "[Activation z-score, 3.359]",
                "[P-value of overlap, 1.99\u00d710^-15]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "SP1",
                "Activation z-score": "2.06",
                "P-value of overlap": "4.79\u00d710^-13"
            },
            "measures": "[Upstream Regulator, SP1]",
            "outcomes": [
                "[Activation z-score, 2.06]",
                "[P-value of overlap, 4.79\u00d710^-13]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "CEBPB",
                "Activation z-score": "2.866",
                "P-value of overlap": "2.62\u00d710^-12"
            },
            "measures": "[Upstream Regulator, CEBPB]",
            "outcomes": [
                "[Activation z-score, 2.866]",
                "[P-value of overlap, 2.62\u00d710^-12]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "NFkB (complex)",
                "Activation z-score": "6.314",
                "P-value of overlap": "1.43\u00d710^-11"
            },
            "measures": "[Upstream Regulator, NFkB (complex)]",
            "outcomes": [
                "[Activation z-score, 6.314]",
                "[P-value of overlap, 1.43\u00d710^-11]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "TBX2",
                "Activation z-score": "4.99",
                "P-value of overlap": "1.62\u00d710^-11"
            },
            "measures": "[Upstream Regulator, TBX2]",
            "outcomes": [
                "[Activation z-score, 4.99]",
                "[P-value of overlap, 1.62\u00d710^-11]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "IRF1",
                "Activation z-score": "3.759",
                "P-value of overlap": "2.76\u00d710^-11"
            },
            "measures": "[Upstream Regulator, IRF1]",
            "outcomes": [
                "[Activation z-score, 3.759]",
                "[P-value of overlap, 2.76\u00d710^-11]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "IRF7",
                "Log Ratio": "1.504",
                "Activation z-score": "5.591",
                "P-value of overlap": "2.88\u00d710^-10"
            },
            "measures": "[Upstream Regulator, IRF7]",
            "outcomes": [
                "[Log Ratio, 1.504]",
                "[Activation z-score, 5.591]",
                "[P-value of overlap, 2.88\u00d710^-10]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "FOXM1",
                "Log Ratio": "2.152",
                "Activation z-score": "4.395",
                "P-value of overlap": "5.12\u00d710^-10"
            },
            "measures": "[Upstream Regulator, FOXM1]",
            "outcomes": [
                "[Log Ratio, 2.152]",
                "[Activation z-score, 4.395]",
                "[P-value of overlap, 5.12\u00d710^-10]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "STAT1",
                "Activation z-score": "4.576",
                "P-value of overlap": "2.05\u00d710^-08"
            },
            "measures": "[Upstream Regulator, STAT1]",
            "outcomes": [
                "[Activation z-score, 4.576]",
                "[P-value of overlap, 2.05\u00d710^-08]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "ETS1",
                "Log Ratio": "0.863",
                "Activation z-score": "2.575",
                "P-value of overlap": "5.06\u00d710^-08"
            },
            "measures": "[Upstream Regulator, ETS1]",
            "outcomes": [
                "[Log Ratio, 0.863]",
                "[Activation z-score, 2.575]",
                "[P-value of overlap, 5.06\u00d710^-08]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "JUN",
                "Activation z-score": "2.045",
                "P-value of overlap": "5.57\u00d710^-08"
            },
            "measures": "[Upstream Regulator, JUN]",
            "outcomes": [
                "[Activation z-score, 2.045]",
                "[P-value of overlap, 5.57\u00d710^-08]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "FOXO1",
                "Activation z-score": "3.242",
                "P-value of overlap": "9.35\u00d710^-08"
            },
            "measures": "[Upstream Regulator, FOXO1]",
            "outcomes": [
                "[Activation z-score, 3.242]",
                "[P-value of overlap, 9.35\u00d710^-08]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "E2F3",
                "Log Ratio": "1.137",
                "Activation z-score": "2.394",
                "P-value of overlap": "1.16\u00d710^-06"
            },
            "measures": "[Upstream Regulator, E2F3]",
            "outcomes": [
                "[Log Ratio, 1.137]",
                "[Activation z-score, 2.394]",
                "[P-value of overlap, 1.16\u00d710^-06]"
            ]
        },
        {
            "subject": {
                "Upstream Regulator": "MBD2",
                "Activation z-score": "2.549",
                "P-value of overlap": "5.41\u00d710^-06"
            },
            "measures": "[Upstream Regulator, MBD2]",
            "outcomes": [
                "[Activation z-score, 2.549]",
                "[P-value of overlap, 5.41\u00d710^-06]"
            ]
        }
    ],
    "PMC3428781_1": [
        {
            "subject": {
                "Quiescent PSCs": "Quiescent PSCs",
                "Activated PSCs": "Activated PSCs"
            },
            "measures": "[phenotype, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "Vitamin A lipid droplets": "Present",
                "\u03b1 Smooth muscle actin": "Absent"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "Proliferation": "Limited",
                "Migration": "Limited"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "Extracellular matrix production": "Limited",
                "Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix proteinases (TIMPs)": "Complement of MMPs and TIMPs to maintain normal ECM turnover"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "Production of cytokines": "Increased (PDGF, TGF\u03b2, CTGF, IL1, IL6, IL15)"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "Capacity for phagocytosis": "Present"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "Proteomic analyses": "Differential expression of proteins related to the cell cytoskeleton, cell metabolism, motility, growth and invasion"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "cell cytoskeleton": "cell metabolism, motility, growth and invasion, Differential expression"
            },
            "measures": "[proteins, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "cell metabolism": "Increased"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "motility": "Increased"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "growth": "Increased"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "invasion": "Increased"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "cytokines": "Increased (PDGF, TGF\u03b2, CTGF, IL1, IL6, IL15)"
            },
            "measures": "[characteristic, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "PDGF": "TGF\u03b2, CTGF, IL1, IL6, IL15, Increased"
            },
            "measures": "[cytokines, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "quiescent": "Quiescent PSCs",
                "activated": "Activated PSCs"
            },
            "measures": "[state, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        },
        {
            "subject": {
                "phenotype": "Characteristics of quiescent and activated PSC phenotypes"
            },
            "measures": "[PSCs, quiescent, activated]",
            "outcomes": "[PSCs, PSCs]"
        }
    ],
    "PMC4941331_3": [
        {
            "subject": {
                "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                "Nuclear HDAC3": "34",
                "Correlation coefficient": "0.440",
                "P-value": "< 0.001"
            },
            "measures": "[Tumor tissue sample, Tumor tissue sample]",
            "outcomes": "[Cytoplasmic CDH1 Low, Cytoplasmic CDH1 Low]"
        },
        {
            "subject": {
                "Tumor tissue sample": "Cytoplasmic CDH1 High",
                "Nuclear HDAC3": "24"
            },
            "measures": "[Tumor tissue sample, Tumor tissue sample]",
            "outcomes": "[Cytoplasmic CDH1 High, Cytoplasmic CDH1 High]"
        },
        {
            "subject": {
                "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                "Nuclear HDAC3": "22"
            },
            "measures": "[Tumor tissue sample, Tumor tissue sample]",
            "outcomes": "[Cytoplasmic CDH1 Low, Cytoplasmic CDH1 Low]"
        },
        {
            "subject": {
                "Association": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression"
            },
            "measures": "[Association]",
            "outcomes": "[Association]"
        },
        {
            "subject": {
                "Citation": "An inverse correlation was identified between low membrane expression of CDH1 and high nuclear HDAC3 expression"
            },
            "measures": "[Citation]",
            "outcomes": "[Citation]"
        },
        {
            "subject": {
                "Citation": "High cytoplasmic CDH1 expression positively correlated with high nuclear HDAC3 expression"
            },
            "measures": "[Citation]",
            "outcomes": "[Citation]"
        },
        {
            "subject": {
                "Citation": "No correlations were found between cytoplasmic HDAC3 expression and CDH1 expression location"
            },
            "measures": "[Citation]",
            "outcomes": "[Citation]"
        },
        {
            "subject": {
                "Citation": "Spearman correlation coefficient r = \u22120.348, P = 0.001, Supplementary Table S1"
            },
            "measures": "[Citation]",
            "outcomes": "[Citation]"
        },
        {
            "subject": {
                "Citation": "Spearman correlation coefficient r = 0.440, P < 0.001, Table 3"
            },
            "measures": "[Citation]",
            "outcomes": "[Citation]"
        },
        {
            "subject": {
                "Citation": "P > 0.05, Supplementary Tables S2, S3"
            },
            "measures": "[Citation]",
            "outcomes": "[Citation]"
        }
    ],
    "PMC6062623_3": [
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Right",
                "Density": "0.1",
                "t-statistic": "-3.76",
                "p-value": "0.002"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -3.76]",
                "[p-value, 0.002]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Right",
                "Density": "0.15",
                "t-statistic": "-3.15",
                "p-value": "0.008"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -3.15]",
                "[p-value, 0.008]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Right",
                "Density": "0.2",
                "t-statistic": "-3.25",
                "p-value": "0.006"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -3.25]",
                "[p-value, 0.006]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Right",
                "Density": "0.25",
                "t-statistic": "-3.08",
                "p-value": "0.009"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -3.08]",
                "[p-value, 0.009]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Left",
                "Density": "0.1",
                "t-statistic": "-1.04",
                "p-value": "0.32"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -1.04]",
                "[p-value, 0.32]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Left",
                "Density": "0.15",
                "t-statistic": "-2.58",
                "p-value": "0.022"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -2.58]",
                "[p-value, 0.022]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Left",
                "Density": "0.2",
                "t-statistic": "-3.36",
                "p-value": "0.005"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -3.36]",
                "[p-value, 0.005]"
            ]
        },
        {
            "subject": {
                "Hypothesis": "State transition",
                "Graph metric": "Local efficiency",
                "Hemisphere": "Left",
                "Density": "0.25",
                "t-statistic": "-3.04",
                "p-value": "0.01"
            },
            "measures": "[Hypothesis, State transition]",
            "outcomes": [
                "[t-statistic, -3.04]",
                "[p-value, 0.01]"
            ]
        }
    ],
    "PMC5464866_2": [
        {
            "subject": {
                "FXR expression": "ranging from negative to strong positive",
                "Cancerous tissues": "88",
                "Adjacent tissues": "88",
                "Number": "88",
                "Positive": "27 (30.7%)",
                "Negative": "61 (69.3%)"
            },
            "measures": "[FXR expression, p < 0.05]",
            "outcomes": "[FXR expression, significant difference]"
        },
        {
            "subject": {
                "FXR expression": "negative",
                "Cancerous tissues": "34 (38.6%)",
                "Adjacent tissues": "61 (69.3%)"
            },
            "measures": "[FXR expression, p < 0.05]",
            "outcomes": ""
        },
        {
            "subject": {
                "FXR expression": "positive",
                "Cancerous tissues": "54 (61.4%)",
                "Adjacent tissues": "27 (30.7%)"
            },
            "measures": "[FXR expression, p < 0.05]",
            "outcomes": ""
        },
        {
            "subject": {
                "FXR expression": "strong positive",
                "Cancerous tissues": "?"
            },
            "measures": "[FXR expression, p < 0.05]",
            "outcomes": ""
        }
    ],
    "PMC5687650_6": [
        {
            "subject": {
                "Risk factors": "Overall survival (OS)",
                "Univariate analysis": "Multivariate analysis",
                "OR (95% CI)": "P value"
            },
            "measures": "[Risk factors, Overall survival (OS)]",
            "outcomes": "[Univariate analysis, Multivariate analysis]"
        },
        {
            "subject": {
                "Gender": "Women or Men",
                "0.770 (0.528-1.124)": "0.175"
            },
            "measures": "[Gender, Women or Men]",
            "outcomes": "[0.770 (0.528-1.124), 0.175]"
        },
        {
            "subject": {
                "Age": ">65 years or \u226465 years",
                "0.773 (0.537-1.110)": "0.163"
            },
            "measures": "[Age, >65 years or \u226465 years]",
            "outcomes": "[0.773 (0.537-1.110), 0.163]"
        },
        {
            "subject": {
                "PLR": "high or low",
                "-": "0.660"
            },
            "measures": "[PLR, high or low]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "NLR": "high or low",
                "-": "0.969"
            },
            "measures": "[NLR, high or low]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Post/pre-chemotherapy PLR ratio": ">1 or \u22641",
                "1.272 (0.881-1.837)": "0.199"
            },
            "measures": "[Post/pre-chemotherapy PLR ratio, >1 or \u22641]",
            "outcomes": "[1.272 (0.881-1.837), 0.199]"
        },
        {
            "subject": {
                "Post/pre-chemotherapy NLR ratio": ">1 or \u22641",
                "1.902 (1.290-2.803)": "0.001**"
            },
            "measures": "[Post/pre-chemotherapy NLR ratio, >1 or \u22641]",
            "outcomes": "[1.902 (1.290-2.803), 0.001**]"
        }
    ],
    "PMC5464866_1": [
        {
            "subject": {
                "Year": "6",
                "FXR expression": "High",
                "Number at risk": "0.0%",
                "Median survival time": "1.78",
                "Survival rate": "0.5241"
            },
            "measures": "[Year, Year, FXR expression, Number at risk, Median survival time, Survival rate]",
            "outcomes": "[0, 2, 4, 6, Low, High, 87, 49.7%, 16, 9.1%, 6, 3.4%, 1, 0.6%, 88, 50.3%, 9, 5.1%, 3, 1.7%, 0, 0.0%, 1.83, 1.78, 0.4288, 0.3020, 0.6089, 0.3127, 0.1776, 0.5503, 0.3036, 0.1646, 0.5600, 0.2277, 0.0989, 0.5241]"
        }
    ],
    "PMC5641200_3": [
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Red blood cells count decreased]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptididase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Leukopenia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Neutropenia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, AST increase]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, ALT increase]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, GGT increase]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Hypocalcemia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Hyponatremia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Nausea]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Vomiting]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Diarrhea]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Abdominal pain]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Oral mucositis]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Dyspepsia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Dysgeusia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Anorexia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Alopecia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 6]",
                "[AE, Fatigue]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 4]",
                "[AE, Pneumonitis]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 4]",
                "[AE, Peripheral sensory neuropathy]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 4]",
                "[AE, Arthralgia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 4]",
                "[AE, Myalgia]",
                "[G, G1]"
            ]
        },
        {
            "subject": {
                "Treatment": "Dasatinib",
                "Dose Level": "mg",
                "n": "number of patients",
                "AE": "adverse event",
                "G": "grade",
                "AST": "aspartate aminotransferase",
                "ALT": "alanine aminotransferase",
                "GGT": "gamma-glutamyl transpeptidase",
                "LVEF": "left ventricular ejection fraction"
            },
            "measures": "[Treatment, Dasatinib]",
            "outcomes": [
                "[Dose Level, mg]",
                "[n, 4]",
                "[AE, LVEF decrease]",
                "[G, G1]"
            ]
        }
    ],
    "PMC5716794_2": [
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "55",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.70",
                "AUC \u00b1 SE (95% CI)": "0.687 \u00b1 0.079 (0.575\u22120.785)",
                "Sensitivities (95% CI)": "89.1 (78.8 \u221295.5)",
                "Specificities (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.4",
                "NPV (%)": "56.3",
                "ACC (%)": "80.5"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "82",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.72",
                "AUC \u00b1 SE (95% CI)": "0.694 \u00b1 0.077 (0.582\u22120.791)",
                "Sensitivities (95% CI)": "90.6 (80.7 \u221296.5)",
                "Specificities (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.6",
                "NPV (%)": "59.9",
                "ACC (%)": "81.7"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "99",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.73",
                "AUC \u00b1 SE (95% CI)": "0.707\u00b1 0.074 (0.596\u22120.802)",
                "Sensitivities (95% CI)": "90.6 (80.7 \u2013 96.5)",
                "Specificities (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.6",
                "NPV (%)": "59.9",
                "ACC (%)": "81.7"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "134",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.74",
                "AUC \u00b1 SE (95% CI)": "0.731 \u00b1 0.070 (0.622\u22120.823)",
                "Sensitivities (95% CI)": "90.6 (80.7 \u2013 96.5)",
                "Specificities (95% CI)": "50.0 (26.0 \u221274.0)",
                "PPV (%)": "86.6",
                "NPV (%)": "59.9",
                "ACC (%)": "81.7"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "152",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.70",
                "AUC \u00b1 SE (95% CI)": "0.751 \u00b1 0.067 (0.643\u22120.840)",
                "Sensitivities (95% CI)": "89.1 (78.8 \u2013 95.5)",
                "Specificities (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "87.7",
                "NPV (%)": "58.9",
                "ACC (%)": "81.7"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "161",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.70",
                "AUC \u00b1 SE (95% CI)": "0.756 \u00b1 0.065 (0.649\u22120.844)",
                "Sensitivities (95% CI)": "89.1 (78.8 \u2013 95.5)",
                "Specificities (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "87.7",
                "NPV (%)": "58.9",
                "ACC (%)": "81.7"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "189",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.75",
                "AUC \u00b1 SE (95% CI)": "0.770 \u00b1 0.062 (0.664\u22120.856)",
                "Sensitivities (95% CI)": "90.6 (80.7 \u2013 96.5)",
                "Specificities (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "87.9",
                "NPV (%)": "62.5",
                "ACC (%)": "82.9"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "214",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.79",
                "AUC \u00b1 SE (95% CI)": "0.788 \u00b1 0.059 (0.684\u22120.871)",
                "Sensitivities (95% CI)": "92.2 (82.7 \u2013 97.4)",
                "Specificities (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "88.1",
                "NPV (%)": "66.7",
                "ACC (%)": "84.2"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "223",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.79",
                "AUC \u00b1 SE (95% CI)": "0.793 \u00b1 0.058 (0.689\u22120.874)",
                "Sensitivities (95% CI)": "93.8 (84.8 \u2013 98.3)",
                "Specificities (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "88.3",
                "NPV (%)": "71.6",
                "ACC (%)": "85.4"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        },
        {
            "subject": {
                "ROI size (mm<sup>2</sup>)": "245",
                "Optimal cutoff values (\u00d7 10<sup>\u22123</sup>mm<sup>2</sup>/s)": "1.79",
                "AUC \u00b1 SE (95% CI)": "0.800 \u00b1 0.056 (0.697\u22120.881)",
                "Sensitivities (95% CI)": "95.3 (86.9 \u2013 99.0)",
                "Specificities (95% CI)": "55.6 (30.8 \u221278.5)",
                "PPV (%)": "88.4",
                "NPV (%)": "76.9",
                "ACC (%)": "86.6"
            },
            "measures": "[ROI size, Optimal cutoff values, AUC, Sensitivities, Specificities, PPV, NPV, ACC]",
            "outcomes": ""
        }
    ],
    "PMC3757392_2": [
        {
            "subject": {
                "Cell line": "Capan-1",
                "Vector": "C595:MUC1",
                "ICC": "++",
                "Flow": "40",
                "Confocal": "++",
                "Do": "170"
            },
            "measures": "[Cell line, Vector, ICC, Flow, Confocal, Do]",
            "outcomes": "[Pancreatic cancer cell line, C595:MUC1, ++, 40, ++, 170]"
        },
        {
            "subject": {
                "Cell line": "Cfpac-1",
                "Vector": "C595:MUC1",
                "ICC": "+++",
                "Flow": "500",
                "Confocal": "+++",
                "Do": "140"
            },
            "measures": "[Cell line, Vector, ICC, Flow, Confocal, Do]",
            "outcomes": "[Pancreatic cancer cell line, C595:MUC1, +++, 500, +++, 140]"
        },
        {
            "subject": {
                "Cell line": "Panc-1",
                "Vector": "C595:MUC1",
                "ICC": "+++",
                "Flow": "80",
                "Confocal": "+++",
                "Do": "160"
            },
            "measures": "[Cell line, Vector, ICC, Flow, Confocal, Do]",
            "outcomes": "[Pancreatic cancer cell line, C595:MUC1, +++, 80, +++, 160]"
        },
        {
            "subject": {
                "Cell line": "Capan-1",
                "Vector": "394:uPA",
                "ICC": "++",
                "Flow": "88",
                "Confocal": "++",
                "Do": "190"
            },
            "measures": "[Cell line, Vector, ICC, Flow, Confocal, Do]",
            "outcomes": "[Pancreatic cancer cell line, 394:uPA, ++, 88, ++, 190]"
        },
        {
            "subject": {
                "Cell line": "Cfpac-1",
                "Vector": "394:uPA",
                "ICC": "+++",
                "Flow": "92",
                "Confocal": "+++",
                "Do": "130"
            },
            "measures": "[Cell line, Vector, ICC, Flow, Confocal, Do]",
            "outcomes": "[Pancreatic cancer cell line, 394:uPA, +++, 92, +++, 130]"
        },
        {
            "subject": {
                "Cell line": "Panc-1",
                "Vector": "394:uPA",
                "ICC": "+++",
                "Flow": "91",
                "Confocal": "+++",
                "Do": "170"
            },
            "measures": "[Cell line, Vector, ICC, Flow, Confocal, Do]",
            "outcomes": "[Pancreatic cancer cell line, 394:uPA, +++, 91, +++, 170]"
        },
        {
            "subject": {
                "Immunoreactivity": "strong",
                "MUC-1 expression": "cell membrane",
                "Confocal microscopy": "green image",
                "Flow cytometry": "purple peak"
            },
            "measures": "[Immunoreactivity, MUC-1 expression, Confocal microscopy, Flow cytometry]",
            "outcomes": "[Pancreatic cancer cell line, strong, cell membrane, green image, purple peak]"
        },
        {
            "subject": {
                "Citations": "MUC1",
                "Immunoreactivity": "strong",
                "MUC-1 expression": "cell membrane",
                "Confocal microscopy": "green image",
                "Flow cytometry": "purple peak"
            },
            "measures": "[Citations, Immunoreactivity, MUC-1 expression, Confocal microscopy, Flow cytometry]",
            "outcomes": "[Pancreatic cancer cell line, MUC1, strong, cell membrane, green image, purple peak]"
        },
        {
            "subject": {
                "Table": "Comparison of cell line properties"
            },
            "measures": "[Table, Comparison of cell line properties]",
            "outcomes": ""
        },
        {
            "subject": {
                "Caption": "Comparison of cell line properties"
            },
            "measures": "[Caption, Comparison of cell line properties]",
            "outcomes": ""
        }
    ]
}